Report cover image

Head and Neck Cancer Therapeutics

Publisher Global Industry Analysts
Published Jun 01, 2025
Length 93 Pages
SKU # GJOB20113082

Description

Global Head and Neck Cancer Therapeutics Market to Reach US$2.7 Billion by 2030

The global market for Head and Neck Cancer Therapeutics estimated at US$2.0 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the EGFR Inhibitors segment is estimated at -5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$535.1 Million While China is Forecast to Grow at 9.7% CAGR

The Head and Neck Cancer Therapeutics market in the U.S. is estimated at US$535.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$575.4 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Head and Neck Cancer Therapeutics Market - Key Trends and Drivers Summarized

How Are Advances in Head and Neck Cancer Therapeutics Transforming Oncology?

The head and neck cancer therapeutics market has seen remarkable advancements with the development of targeted therapies, immunotherapies, and personalized medicine approaches. Head and neck cancers, including those affecting the oral cavity, pharynx, and larynx, are often linked to factors such as tobacco use, alcohol consumption, and human papillomavirus (HPV) infection. The complexity of these cancers requires a multi-modal treatment approach that includes surgery, radiation, chemotherapy, and emerging biologic therapies. Immunotherapy, particularly immune checkpoint inhibitors, is revolutionizing treatment by enabling the immune system to target and destroy cancer cells, offering new hope for patients with advanced or recurrent cancers.

What Are the Major Segments in the Head and Neck Cancer Therapeutics Market?

Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with immunotherapy showing promising results in cases where traditional treatments fail. Types of head and neck cancers covered include squamous cell carcinoma, nasopharyngeal carcinoma, and oropharyngeal cancer, among others. End-users include hospitals, oncology clinics, and specialized cancer treatment centers. The rise in early detection through advanced diagnostic tools and personalized treatment plans is improving patient outcomes and expanding the market for head and neck cancer therapies.

How Are Technological Innovations Driving New Therapies for Head and Neck Cancer?

Technological advancements in cancer research are driving innovation in head and neck cancer treatments. The introduction of precision medicine is allowing oncologists to tailor treatments based on the genetic profile of a patient’s tumor, leading to more effective therapies with fewer side effects. Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab and nivolumab, is at the forefront of therapeutic innovation, offering improved survival rates for patients with advanced cancers. Additionally, advancements in radiation therapy, including intensity-modulated radiation therapy (IMRT), are enabling more precise targeting of tumors, minimizing damage to surrounding healthy tissues. These innovations are transforming the therapeutic landscape for head and neck cancer, providing new avenues for treatment.

What Factors Are Driving the Growth in the Head and Neck Cancer Therapeutics Market?

The growth in the head and neck cancer therapeutics market is driven by several factors, including the increasing prevalence of head and neck cancers globally, rising awareness about early detection, and advancements in cancer treatment modalities. Immunotherapy and targeted therapies are expanding treatment options for patients with difficult-to-treat cancers, contributing to market growth. The growing aging population, which is more susceptible to cancer, is also driving demand for advanced therapeutics. Additionally, increased investment in cancer research, government initiatives to improve access to cancer care, and collaborations between pharmaceutical companies and research institutions are accelerating the development of new and more effective treatments for head and neck cancer.

SCOPE OF STUDY:

The report analyzes the Head and Neck Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -
  • AB Science SA
  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
  • Fresenius Medical Care AG & Co. KGaA
  • Merck
  • Pfizer, Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Limited
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

93 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Global Economic Update
Head and Neck Cancer Therapeutics – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Head and Neck Cancers Drives Growth in Therapeutics Market
Technological Advancements in Immunotherapy and Targeted Therapies Propel Market Adoption
Increasing Focus on Personalized Medicine Expands Addressable Market for Cancer Therapeutics
Growing Demand for Minimally Invasive Treatment Options Spurs Innovation in Therapeutics
Rising Healthcare Expenditure and Access to Advanced Cancer Treatments Expand Market Opportunities
Increasing Use of Combination Therapies for Improved Treatment Outcomes Drives Demand
Growing Focus on Early Detection and Diagnosis Strengthens the Market for Therapeutic Interventions
Rising Adoption of Biomarker-Based Therapies and Diagnostics Generates Market Opportunities
Advances in Radiation Therapy and Chemotherapy Techniques Propel Therapeutic Innovation
Rising Awareness About Cancer Prevention and Treatment Expands Patient Access to Therapeutics
Technological Integration of AI and Precision Medicine in Cancer Therapeutics Enhances Market Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Head and Neck Cancer Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for PD Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for PD Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for PD Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for EGFR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Microtubule Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Microtubule Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Microtubule Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 15: USA Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: USA 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 18: Canada Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: Canada 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
JAPAN
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 21: Japan Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: Japan 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
CHINA
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 23: China Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 24: China Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: China 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
EUROPE
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: Europe Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: Europe 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: Europe 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
FRANCE
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 32: France Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 33: France Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: France 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
GERMANY
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Germany Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: Germany 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: Italy Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: Italy 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
UNITED KINGDOM
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: UK Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: UK 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
SPAIN
TABLE 44: Spain Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: Spain Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: Spain 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
RUSSIA
TABLE 47: Russia Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: Russia Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: Russia 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Rest of Europe Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: Rest of Europe 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 54: Asia-Pacific Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Asia-Pacific 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Asia-Pacific 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
AUSTRALIA
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 59: Australia Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Australia Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Australia 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
INDIA
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 62: India Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: India Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: India 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 65: South Korea Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: South Korea Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: South Korea 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Rest of Asia-Pacific Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: Rest of Asia-Pacific 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
LATIN AMERICA
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 71: Latin America Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 72: Latin America Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: Latin America 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 74: Latin America Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Latin America 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 77: Argentina Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Argentina Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Argentina 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
BRAZIL
TABLE 80: Brazil Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Brazil Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Brazil 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
MEXICO
TABLE 83: Mexico Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Mexico Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Mexico 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Rest of Latin America Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: Rest of Latin America 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
MIDDLE EAST
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 89: Middle East Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 90: Middle East Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: Middle East 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 92: Middle East Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: Middle East 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
IRAN
TABLE 95: Iran Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Iran Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Iran 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
ISRAEL
TABLE 98: Israel Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Israel Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Israel 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Saudi Arabia Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Saudi Arabia 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 104: UAE Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: UAE Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: UAE 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Rest of Middle East Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Rest of Middle East 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
AFRICA
Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 110: Africa Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Africa Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: Africa 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030
IV. COMPETITION

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us